Skip to main content

Table 1 Summary of FDA-approved chemotherapeutic agents investigated in current study by category and subcategory

From: Off-label use of cancer therapies in women diagnosed with breast cancer in the United States

Drug category Drug name Indicated for breast cancer Labeled indications if not indicated for breast cancer (ICD-9 codes) Initial FDA approval during study period
Alkylating agents Carboplatin   183, 198.6 1989
  Carmustine   191,200-202,203.0 1977
  Chlorambucil   200-202,204.1,204.9 1957
  Cisplatin   183,186,188,198.6 1978
  Cyclophosphamide Yes   1959
  Dacarbazine   172,198.2, 201 1975
  Ifosfamide   186 1988
  Mechlorethamine   162.2-162.5,162.8,162.9,197.0,200,201,202.0 1949
    202.1,202.8,204.1,205.1,208.1,238.4,511.9  
  Melphalan   183,1 198.6, 1203.0 1964
  Oxaliplatin   153,154,197.5 August 2002
  Streptozocin   157.4 1982
  Thiotepa Yes   1959
Antimetabolites Azacitidine   205,280-285 May 2004
  Capecitabine Yes   1998
  Cladribine   202.4 1993
  Clofarabine   204.0,204.9 December 2004
  Cytarabine   204.0, 204.9, 205.0, 205.1, 205.9 1969
  Fludarabine   204.1, 204.9 1991
  Fluorouracil Yes   1962
  Gemcitabine Yes2 157.0-157.9, 162.2-162.5, 162.8, 162.9, 197.03 1996
  Hydroxyurea   172.1-172.4, 173.1-173.4, 183, 195.0, 198.2, 198.6, 205.1, 205.9 1967
  Mercaptopurine   204.0, 204.9 1953
  Methotrexate Yes   1953
  Pemetrexed   162.2-162.5, 162.8, 162.9, 163, 197.0 February 2004
Anti-tumor antibiotics Bleomycin   140-149, 160, 161, 180, 184, 186, 187, 195.0, 197.2, 198.82, 200–202, 511 1973
  Dactinomycine Yes4   1964
  Daunorubicin   204.00-204.91, 205.00-205.21, 205.80-205.91, 208.00-208.01 1979
  Doxorubicin Yes   1974
  Epirubicin Yes   1974
  Idarubicin Yes   1999
  Liposomal doxorubicin   205.0, 205.9 1990
  Mitomycin-C   151, 157 1981
Topoisomerase inhibitors Etoposide   162.2-162.5, 162.8, 162.9, 186, 197.0 1983
  Irinotecan   153, 154, 197.5 1996
  Mitoxantrone   185, 205–208, 340 1987
  Topotecan   162.2-162.5, 162.8, 162.9, 180, 183,197.0, 198.6 1996
Anti-mitotic Docetaxel Yes   1996
  Ixabepilone Yes   October 2007
  nab-Paclitaxel Yes   January 2005
  Paclitaxel Yes   1992
  Vinblastine Yes   1965
  Vincristine   171, 189.0, 189.9, 194.0, 194.9, 198.0, 200, 201, 202.0, 202.1, 202.8, 204.0, 204.9 1963
  Vinorelbine   162.3-162.5, 162.8, 162.9 1994
  1. 1Indication for the oral formulation.
  2. 2FDA-approved for breast cancer on December 18, 2004.
  3. 3Indications approved by the FDA before December 18, 2004. Ovarian cancer only included after it was approved by the FDA on July 14 2006.
  4. 4Not breast cancer specifically but locoregional solid tumors.